Bruker (NASDAQ:BRKR) Releases FY 2024 Earnings Guidance

Bruker (NASDAQ:BRKR - Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.790-2.840 for the period, compared to the consensus estimate of 2.710. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BRKR. The Goldman Sachs Group increased their target price on Bruker from $66.00 to $74.00 and gave the company a sell rating in a research note on Wednesday, April 10th. Citigroup raised their price objective on shares of Bruker from $80.00 to $95.00 and gave the stock a buy rating in a research note on Wednesday, February 14th. Stifel Nicolaus upped their target price on shares of Bruker from $63.00 to $81.00 and gave the company a hold rating in a research note on Wednesday, February 14th. JPMorgan Chase & Co. upgraded shares of Bruker from a neutral rating to an overweight rating and raised their price target for the stock from $60.00 to $90.00 in a research report on Wednesday, February 14th. Finally, UBS Group upped their price objective on shares of Bruker from $94.00 to $102.00 and gave the company a buy rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $84.86.

Bruker Stock Down 0.1 %

NASDAQ BRKR traded down $0.05 during trading hours on Friday, reaching $70.05. 1,959,840 shares of the company's stock were exchanged, compared to its average volume of 860,901. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.99 and a current ratio of 1.80. The company has a market capitalization of $10.18 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 2.00 and a beta of 1.22. The company's 50-day moving average is $87.68 and its two-hundred day moving average is $75.00. Bruker has a one year low of $53.79 and a one year high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.07. Bruker had a return on equity of 29.94% and a net margin of 14.41%. The company had revenue of $721.70 million during the quarter, compared to analysts' expectations of $729.88 million. During the same period in the prior year, the firm earned $0.64 earnings per share. Bruker's revenue for the quarter was up 5.3% compared to the same quarter last year. On average, analysts forecast that Bruker will post 2.74 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date was Thursday, February 29th. Bruker's dividend payout ratio is presently 6.85%.

Insider Activity at Bruker

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the business's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the sale, the director now directly owns 23,147 shares of the company's stock, valued at approximately $2,084,618.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 28.30% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.